NCT02813434CompletedPhase 3
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
Cerebral Amyloid Imaging Using Florbetapir (18F-AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 92 (actual)
- First submitted
- 20 Jun 2016
- Start date
- Sept 2014
- Primary completion date
- Jan 2025
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- NCT number
- NCT02813434
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 92
- From Sept 2014 to the primary completion date, Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patient receiving any investigational medications at least in the 30 last days,
Other illness
- history of relevant severe drug allergy or hypersensitivity,
- stroke affecting the cerebellum,
- dementia diagnosed before stroke,
- history of schizophrenia or psychiatric illness requiring a stay for \> 2 days in a psychiatry unit,
- comorbidities affecting cognition (respiratory, renal, liver, heart failure),
- persistent disturbance of consciousness defined by a score to item 1a of the National Institute of Health Stroke Scale (NIHSS) ≤ 1,
Other
- women of childbearing potential (defined as pre-menopausal, less than 2 years postmenopausal, or not surgically sterile), or who are breast-feeding
- mental retardation,
- illiteracy,
- persons placed under judicial protection,
- contraindication to MRI.
Who the study is looking for
- patients suffering of parenchymal stroke visualized by imaging (MRI),
- patients suffering from cognitive impairment on the 6 months assessment (including GRECogVASC patients),
- age between 40 and 80 years,
- French-speaking,
- reliable informant,
- agreeing to participate in the study,
- affiliation to a social security system,
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.